Levy AS, Krailo M, Chi S, Villaluna D, Springer L, Williams-Hughes C, Fouladi M, Gajjar A. Temozolomide with irinotecan versus temozolomide, irinotecan plus bevacizumab for recurrent medulloblastoma of childhood: Report of a COG randomized Phase II screening trial. Pediatr Blood Cancer. 2021 Aug;68(8):e29031. doi: 10.1002/pbc.29031. Epub 2021 Apr 12. PubMed PMID: 33844469; PubMed Central PMCID: PMC8764558.
Study ID Citation
Abstract
Approximately 30% of children with medulloblastoma (MB) experience recurrence which is usually incurable. This study compared the overall survival (OS) of patients receiving temozolomide (TMZ) and irinotecan with that of patients receiving TMZ, irinotecan and bevacizumab for recurrent MB/CNS primitive neuroectodermal tumor (PNET). Patients with relapsed/refractory MB or CNS PNET were randomly assigned to receive TMZ (150 mg/m2/day PO on days1-5) and irinotecan (50 mg/m2/day IV on days 1-5) with or without bevacizumab (10 mg/kg IV on days 1 and 15).